News headlines about Enzo Biochem (NYSE:ENZ) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enzo Biochem earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 45.419973957217 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Enzo Biochem (NYSE:ENZ) traded up $0.09 during midday trading on Wednesday, hitting $6.90. The stock had a trading volume of 107,948 shares, compared to its average volume of 187,128. The stock has a market capitalization of $323.79, a P/E ratio of -172.50 and a beta of 0.70. Enzo Biochem has a twelve month low of $6.38 and a twelve month high of $12.04.
Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Thursday, December 7th. The medical research company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). Enzo Biochem had a negative return on equity of 1.89% and a negative net margin of 1.53%. The firm had revenue of $27.68 million during the quarter, compared to the consensus estimate of $27.51 million.
In other news, CEO Elazar Rabbani sold 14,000 shares of the stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total transaction of $108,500.00. Following the transaction, the chief executive officer now owns 1,867,202 shares of the company’s stock, valued at approximately $14,470,815.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Barry W. Weiner sold 11,000 shares of the stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $7.75, for a total value of $85,250.00. Following the transaction, the chief financial officer now directly owns 1,313,111 shares in the company, valued at approximately $10,176,610.25. The disclosure for this sale can be found here. 8.90% of the stock is owned by company insiders.
WARNING: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/14/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-enzo-biochem-enz-stock-price.html.
About Enzo Biochem
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.